Invivogen MPLA Synthetic VacciGrade, 1 mg
MPLA is a low-toxicity derivative of lipopolysaccharide (LPS), that retains the immunologically active lipid A portion of the parent molecule. While the toxicity associated with LPS prohibits its potential clinical use, MPLA is being developed as a vaccine adjuvant. Both LPS and MPLA are TLR4 agonists, but they signal through different adaptors, MyD88 and TRIF, respectively. The reduced toxicity of MPLA is attributed to the preferential recruitment of TRIF upon TLR4 activation, resulting in decreased induction of inflammatory cytokines.